Axsome Therapeutics, Inc. - 8-K Filing
FDA accepts Axsome's NDA for AXS-12 to treat cataplexy in narcolepsy with PDUFA date set for May 1, 2027 (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $AXSM
More Regulatory news
- XBiotech Inc. - 10-Q Filing
- Cohen & Co Inc. - 10-Q Filing
- UNITED BANCORP INC /OH/ - 10-Q Filing
- PATRIOT GOLD CORP - 10-Q Filing
- First Digital Acquisition Corp Ltd. - 8-K Filing
- GROOVE BOTANICALS INC. - 10-Q Filing
- Johnson Controls International plc - 10-K Filing
- OLD NATIONAL BANCORP /IN/ - 8-K Filing
- AMTECH SYSTEMS INC - 8-K Filing
- REGIONAL HEALTH PROPERTIES, INC - 8-K Filing